Finance

Lists
Q2 2026 earnings • released • EPS beat +146.33% • Revenue beat +105.59%
See results
MCRB:NASDAQ
Seres Therapeutics Inc
$4.87
+1.04%
(+0.050) 1D
$4.70
-3.49% (-0.17)
After hours
Closed: Aug 7, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MCRB...
Open
$5.07
High
$5.19
Low
$4.82
Mkt. cap
48.41M
Avg. vol.
104.62K
Volume
62.32K
52-wk high
$29.98
52-wk low
$4.59
EPS
-$5.08
Beta
0.20
Shares outstanding
9.94M
No. of employees
66
Open
$5.07
High
$5.19
Low
$4.82
Mkt. cap
48.41M
Avg. vol.
104.62K
Volume
62.32K
52-wk high
$29.98
52-wk low
$4.59
EPS
-$5.08
Beta
0.20
Shares outstanding
9.94M
No. of employees
66
News stories
From sources across the web
About Seres Therapeutics Inc
CEOEric Shaff
Employees66
Founded2010
Headquarters-
SectorBiotechnology
Websiteserestherapeutics.com
Analyst ratings
Based on 2 analysts giving stock ratings to MCRB in the past 3 months
Buy
Buy
2
Hold
0
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for MCRB in the last 3 months.
Highest
Current $4.87
$22.00 (+351.75%)
Average
$17.00 (+249.08%)
Lowest
$12.00 (+146.41%)
Analyst
Recommendation
Action
Price target
Projected
Date
John Newman
Canaccord Genuity
Buy
Maintained
$22.00
+351.7%
08/06/2026
Matthew Keller
H.C. Wainwright
Buy
Reiterated
$12.00
+146.4%
08/05/2026
Edward Tenthoff
Piper Sandler
Hold
Maintained
$20.00
+310.7%
02/13/2026
Joseph Thome
TD Cowen
Buy
Maintained
-
-
11/05/2025
Last report
Aug 5, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$1.07 / -$2.30
+146.33%beat
Revenue / Est. (USD)
736.00K / 358.00K
+105.59%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
351.00K
438.00K
358.00K
736.00K
Cost of goods sold
13.35M
12.28M
13.20M
-
Cost of revenue
13.35M
12.28M
13.20M
-
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
9.48M
7.54M
8.07M
-
Operating expense
9.48M
7.54M
8.07M
-
Total operating expenses
22.83M
19.82M
21.26M
-
Operating income
-22.48M
-19.38M
-20.91M
-
Other non operating income
2.84M
2.33M
669.00K
-
EBT including unusual items
8.20M
-15.34M
-19.91M
-
EBT excluding unusual items
-19.02M
-16.60M
-19.91M
-
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
8.20M
-15.34M
-19.91M
-
Net profit margin
2,337.32%
-3,501.14%
-5,562.29%
622.42%
Earnings per share
0.94
-1.76
-2.08
1.07
Interest and investment income
618.00K
445.00K
325.00K
-
Interest expense
-
-
-
-
Net interest expenses
618.00K
445.00K
325.00K
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-21.43M
-18.42M
-20.13M
-
Gain or loss from assets sale
-
-192.00K
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps